Real-world study links Ozempic 2 mg with lower MACE vs Mounjaro

Novo’s Ozempic (semaglutide) 2 mg was associated with a lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro (tirzepatide), in real-world analysis at EASD.